Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

PPO 20-056 – HSR&D Study

New | Current | Completed | DRA | DRE | Portfolios/Projects | Centers | Career Development Projects

PPO 20-056
Discontinuation of levothyroxine therapy for patients with subclinical hypothyroidism: a pilot randomized, double-blinded, placebo-controlled study
Spyridoula Maraka MD MS
No. Little Rock, AR
Funding Period: March 2021 - August 2022

Abstract

Background: Subclinical hypothyroidism (SCH) is an increasingly common biochemical diagnosis made by finding mildly elevated thyroid stimulating hormone (TSH) yet normal thyroxine levels, affecting up to 200 in 1000 adults, of whom 135 will have nonspecific symptoms and the rest will have no symptoms at all. Following clinical practice guidelines from endocrine societies, SCH is often treated with levothyroxine (LT4). The prevalence of LT4-treated SCH has doubled from 1996 to 2006. More strikingly, LT4 has become the most prescribed drug in the U.S., surpassing opioids. However, no benefits of LT4 have been demonstrated on quality of life (QoL) or thyroid-related symptoms and little or no effect on cardiovascular events or mortality for patients with SCH. Yet, ~50% of patients older than 65 who take LT4 develop iatrogenic hyperthyroidism, increasing their risk for arrhythmias, angina pectoris, bone loss, and fractures. Based on this evidence, a guideline panel recently formulated a strong recommendation against routine LT4 use in most adults with SCH. Significance/Impact: There is clear evidence for overdiagnosis and overtreatment of patients with SCH, causing a substantial and unnecessary economic and treatment burden, and even harm. Once started, 9 in 10 patients with SCH continue LT4 therapy indefinitely. There is no evidence regarding the acceptability, feasibility, safety, and effects on QoL of discontinuing LT4 therapy among patients with SCH who have been previously started on LT4 therapy. Our study, consistent with the VA HSR&D priority area: Quality/Safety, will address these knowledge gaps and has the potential to improve the care delivered to thousands of Veterans. Innovation: This is the first study evaluating the acceptability and feasibility of discontinuing LT4 therapy among patients with treated SCH. This is also the first pilot randomized, double-blind, placebo-controlled trial to evaluate the safety and effects on QoL of discontinuing LT4 therapy in patients with SCH. Successful completion of this novel work will lay the foundation for the implementation of evidence-based care for Veterans with SCH and will contribute to addressing the national epidemic of LT4 overuse. Specific Aims: We propose a pilot study to address the following interrelated hypotheses: LT4-treated SCH is a highly prevalent condition among Veterans. Discontinuation of LT4 for Veterans with SCH will be feasible, acceptable, and safe, and will not negatively affect their QoL. In this proposal we aim to: 1) Identify the prevalence of LT4-treated SCH among Veterans. 2) Evaluate the feasibility of LT4 discontinuation among Veterans with SCH and determine the changes in QoL measures, blood lipids, and adverse events. 3) Assess the acceptability of LT4 discontinuation among Veterans with SCH and LT4-prescribing clinicians. Methodology: We will conduct a retrospective cohort study using the Corporate Data Warehouse through the VA Informatics and Computing Infrastructure and electronic medical records review to identify Veterans aged 18-89 years, diagnosed with SCH and treated with LT4 between January 1, 2009 and December 31, 2019 at CAVHS. We will then conduct a double-blind, placebo-controlled clinical trial where 50 Veterans receiving LT4 for SCH will be randomized 1:1 to continued LT4 or placebo. The primary outcome is feasibility (willingness to enter the trial, recruitment rate, and completion rate). Secondary outcomes are changes in QoL measures (Thyroid-specific QoL Patient-Reported Outcome-Hypothyroid Symptoms and Tiredness scores, EuroQoL 5- Dimension Self-Report Questionnaire) assessed at baseline, 6-8 weeks and 6 months after randomization, changes in blood lipids assessed at baseline and 6 months after randomization, and incidence of adverse events (overt hypothyroidism, hyperthyroidism, cardiovascular events, fractures, mortality). We will assess acceptability of LT4 discontinuation with semi-structured interviews of Veterans and 10 LT4 prescribers. Implementation/Next Steps: This study will test the feasibility, safety, and acceptability of discontinuing LT4 in patients with SCH and will pave the way to design an intervention to be tested in a large multi-site trial.

External Links for this Project

NIH Reporter

Grant Number: I21HX003268-01A1
Link: https://projectreporter.nih.gov/project_info_description.cfm?aid=10184448



Dimensions for VA

       [ Click here for info about Dimensions for VA ] Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
PUBLICATIONS:
None at this time.

DRA: Other Conditions
DRE: TRL - Applied/Translational
Keywords: Best Practices, Guideline Development and Implementation, Pharmacology, Practice Patterns/Trends, Safety Measurement Development
MeSH Terms: None at this time.

Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.